ZFA-Logo

How Important is Sitagliptin in the Treatment of People with Type 2 Diabetes?

DOI: 10.3238/zfa.2019.0150-0155

PDF german translation / full article

Günther Egidi

Keywords: DPP4 inhibitors gliptins sitagliptin sulfonylureas type 2 diabetes

Background: The number of diabetes diagnoses in Germany is increasing. In terms of prescription numbers, DPP4 inhibitors have now overtaken the sulfonylureas in Germany, including sitagliptin. The question arises whether there are good arguments for such a prescription behavior.Search method: Selective literature research on prevalence, complications and treatment of diabetes; research in Medline and Cochrane for sitagliptin.Main messages: Diabetes is a significant health problem in Germany. For sitagliptin, there is no evidence for the reduction of relevant endpoints. However, corresponding studies exist for the much cheaper sulfonylureas glibenclamide and gliclazide.Conclusions: Sitagliptin has no value in the treatment of people with type 2 diabetes. At best for people with diabetes and advanced renal failure, sitagliptin may be an option if insulin is categorically rejected or otherwise inappropriate


(State: 15.04.2019)

Latest Issue 4/2019

In Focus

  • How Important is Sitagliptin in the Treatment of People with Type 2 Diabetes?
  • Understanding the Therapeutic Context
  • “It is one of my most important tasks, to accompany them until the very end”